Boston Scientific’s AngioJet ZelanteDVT catheter approved in EU and US

Boston Scientific has announced that its new AngioJet ZelanteDVT thrombectomy catheter has received regulatory approval in the EU and US.

The catheter is intended to treat deep vein thrombosis (DVT) in large-diameter upper and lower limb peripheral veins and represents is the first AngioJet catheter designed specifically to treat DVT.

It offers four times the thrombus removal power of current market-leading AngioJet catheters and is optimised to efficiently remove large venous clot burdens and facilitate rapid restoration of blood flow.

In doing so, the device is able to potentially decrease procedural time, quickly relieve symptoms and reduce the rate of late complications.

Jeff Mirviss, president for Boston Scientific's peripheral interventions business, said: "With this addition to our AngioJet portfolio, we are further evolving the current suite of life-changing therapeutic options available to physicians and their patients with deep vein thrombosis."

This comes after the firm received European regulatory approval for its Watchman FLX left atrial appendage closure device last month.